Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11129744 | 0.97 | KIF11 (0.71) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5087101 | 0.97 | KIF11 (0.71) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL5091721 | 0.97 | KIF11 (0.71) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL5088281 | 0.97 | KIF11 (0.71) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2679441 | 0.85 | KIF11 (1.00) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Water SCHEMBL11129297 | 0.83 | KIF11 (0.95) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL14976365 | 0.83 | KIF11 (0.95) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1149158 | 0.83 | KIF11 (0.64) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6226052 | 0.81 | KIF11 (0.83) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27656873 | 0.81 | KIF11 (0.62) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661841-A | Prodrug molecule based on zwitterionic polyamide-amine dendrimer, nano drug-loaded micelle, and preparation method and application thereof | 燕山大学 | 2025-03-21 | — | — | CN | disclosed |
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2265283-A1 | AURISTATIN DRUG LINKER CONJUGATES | Seattle Genetics, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2009117531-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7408023-B2 | Peptoids incorporating chemoselective functionalities | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2007113386-A1 | PEPTIDE CONJUGATES | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | CHIRON CORPORATION | 2002-11-14 | — | — | US | disclosed |
| WO-2002081637-A2 | PEPTIDES INCORPORATING CHEMOSELECTIVE FUNCTIONALITIES | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1189971-A2 | FUNCTIONAL POLY-ALPHA-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION | UNIVERSITEIT GENT (BE) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000078791-A2 | FUNCTIONAL POLY-α-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION | UNIVERSITEIT GENT (BE) | 2000-12-28 | — | — | WO | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169281-A1 | Peptoids incorporating chemoselective functionalities | VIP, PCNA, DNPEP | KIF11 3599/4885KCNH2 4391/4885CYP3A4 3225/4885 |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | KIF11 1930/4885KCNH2 2297/4885CYP3A4 1043/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | KIF11 1930/4885KCNH2 2297/4885CYP3A4 1043/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | KIF11 4833/4885KCNH2 4412/4885CYP3A4 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.